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Introduction
Oxcarbazepine is a derivative of carbamazepine that is used primarily in the
treatment of epilepsy, and experimentally as a mood-stabilizer in adjunctive
therapy for the treatment of bipolar disorder. Oxcarbazepine is converted
through oxidation to its pharmacologically active metabolite
10-OH-Carbazepine, which is thought to be responsible for most of the
anticonvulsant action of the drug. Adverse effects of oxcarbazepine are
generally dose-dependent and may include fatigue, somnolence, dizziness,
diplopia, nystagmus, and ataxia. Additive sedative effects have been noted
when oxcarbazepine is used in combination with other CNS depressionproducing medications. Furthermore, oxcarbazepine and 10-OH-Carbazepine
are powerful CYP2C19 inhibitors, potentially increasing the plasma
concentration and pharmacological response of CYP2C19 substrates such as
diazepam. The therapeutic range for oxcarbazepine is based on the
metabolite and extends from 6-35 μg/mL. Toxicity has been reported with
10-OH-Carbazepine levels as low as 65 μg/mL, and one fatality has been
documented with a 10-OH-Carbazepine concentration of 92 μg/mL.
Hydrocodone is a narcotic analgesic that undergoes demethylation and
reduction to produce several pharmacologically active metabolites, including
hydromorphone, norhydrocodone, and dihydrocodeine (6-α-hydrocodol),
which contribute to its efficacy. Hydrocodone toxicity may be characterized
by respiratory depression, drowsiness, and coma. Therapeutic blood and
plasma concentrations of hydrocodone typically range from 10-50 ng/mL,
while levels greater than 100 ng/mL are considered toxic, and concentrations
exceeding 200 ng/mL can be potentially fatal.
Diazepam is a benzodiazepine known for its efficacy and rapid onset.
Therapeutic ranges of diazepam and its metabolite nordiazepam in blood and
plasma measure between 200-2500 ng/mL. Diazepam toxicity may result in
drowsiness, weakness, ataxia, and coma; however, serious and fatal effects
are uncommon with diazepam if used singularly. Most terminal adverse
events associated with diazepam are the result of interaction or combination
with other drugs, especially CNS depressants.

Methods
Postmortem heart blood, femoral blood, urine, vitreous fluid, gastric contents,
and liver and brain tissue were submitted for toxicological analysis. Routine
screening of heart blood was performed using Enzyme Multiplied
Immunoassay Technique (EMIT) and liquid-liquid alkaline extraction
followed by gas chromatography/mass spectrometry (GC/MS) analysis.
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10-OH-Carbazepine as well as hydrocodone and its metabolites were
quantified in femoral blood by an external laboratory using liquid
chromatography/tandem mass spectrometry (LC-MS/MS). Diazepam and
nordiazepam quantitation was performed on heart blood using high
performance liquid chromatography (HPLC).
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Results

Conclusion
The most significant finding in this case is the
10-OH-Carbazepine concentration of 180 μg/mL, which is greater
than the highest known fatal level of 92 μg/mL.

Objective
To present a case of a polysubstance related suicide involving the synergistic
effect of toxic concentrations of oxcarbazepine and hydrocodone in
combination with the presence of diazepam.
To report the highest blood concentration of 10-OH-Carbazepine
found in literature for a drug-related death investigation.
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Case History

The cause of death in this case was ruled oxcarbazepine and
hydrocodone intoxication with diazepam use, and the manner of
death was suicide.

Presented in this case is a 67-year-old female with a history of depression, psychiatric
hospitalization, and previous suicide attempts. The decedent was found lying supine in bed with
a bottle of hydrocodone in one hand and a can of soda in the other, next to a suicide note.
Several other prescription medications, including oxcarbazepine, gabapentin, diazepam,
quetiapine, tizanidine, and lorazepam were found at the scene.
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